BiomX Phage Therapy Shows Potent Effect in Cystic Fibrosis Trial

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis - BiomX (AMEX:PHGE)

Premier research journal article provides validation for BiomX's phage therapy platform, showcasing first-in-human Phase 1b/2a trial results for antibiotic-resistant P. aeruginosa infectionsNew, updated data demonstrates a further bacteria reduction of 2.7 log₁₀ (approximately 500-fold) compared to placebo, with no emergent resistance and preservation of a healthy microbiomeBiomX is advancing its Phase 2b trial of BX004 with topline results expe…

BiomX phage therapy shows potent effect in cystic fibrosis trial

BX004 achieves 500-fold bacterial reduction with no resistance in phase 1b/2a study